98%
921
2 minutes
20
The rapid advancement of artificial intelligence has enabled breakthroughs in diverse fields, including autonomous systems and medical diagnostics. However, conventional deterministic neural networks struggle to capture uncertainty, limiting their reliability when handling real-world data, which are often noisy, imbalanced, or scarce. Bayesian neural networks address this limitation by representing weights as probabilistic distributions, allowing for natural uncertainty quantification and improved robustness. Despite their advantages, hardware-based implementations face significant challenges due to the difficulty of independently tuning both the mean and variance of weight distributions. Herein, we propose a 3D ferroelectric NAND-based Bayesian neural network system that leverages incremental step pulse programming technology to achieve efficient and scalable probabilistic weight control. The page-level programming capabilities and intrinsic device-to-device variations enable gaussian weight distributions in a single programming step, without structural modifications. By modulating the incremental step pulse programming voltage step, we achieve precise weight distribution control. The proposed system demonstrates successful uncertainty estimation, enhanced energy efficiency, and robustness to external noise for medical images.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297355 | PMC |
http://dx.doi.org/10.1038/s41467-025-61980-y | DOI Listing |
Arch Cardiovasc Dis
September 2025
Department of Orthopaedics, Shaoxing Keqiao Women & Children's Hospital, Shaoxing 312030, Zhejiang, China. Electronic address:
Background: Sacubitril/valsartan is a widely used cardiovascular agent characterized by its dual inhibition of the renin-angiotensin-aldosterone system and neprilysin. However, existing evidence on the safety of sacubitril/valsartan is primarily limited to clinical studies; this results in an inability to provide a timely update on associated adverse events.
Aim: To mine and systematically describe adverse events related to sacubitril/valsartan from September 2015 to June 2024 using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Cereb Cortex
August 2025
Department of Developmental Psychology, University of Amsterdam, Nieuwe Achtergracht 129b, 1018 WS Amsterdam, The Netherlands.
Social learning, a hallmark of human behavior, entails integrating other's actions or ideas with one's own. While it can accelerate the learning process by circumventing slow and costly individual trial-and-error learning, its effectiveness depends on knowing when and whose information to use. In this study, we explored how individuals use social information based on their own and others' levels of uncertainty.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Pharmacy, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Maternity and Child Health Hospital, Fujian Medical University, #18 Daoshan Road, Fuzhou, Fujian, 350001, China.
Postpartum hemorrhage (PPH) is a life-threatening obstetric complication. We aimed to identify the drugs that associated with PPH based on the FDA Adverse Event Reporting System (FAERS) data, providing scientific evidence for targeted prevention of drug-related PPH risk factors. Data from 2004Q1 to 2025Q1 were extracted from FAERS, and disproportionality analysis was performed to identify potential drug signals.
View Article and Find Full Text PDFAndrology
September 2025
Department of Urology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China.
Background: Drug-induced hypogonadism is an underrecognized but significant adverse effect of various medications, contributing to male sexual dysfunction and infertility. Despite its clinical significance, comprehensive studies systematically identifying high-risk drugs remain limited.
Objectives: This study aimed to investigate the potential drugs associated with hypogonadism from FDA Adverse Event Reporting System.
PLoS One
September 2025
Geriatric Medicine Center, Department of Nursing, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Background: In recent years, with the expanding use of novel therapeutics such as immune checkpoint inhibitors and monoclonal antibodies, reports of drug-induced vitiligo have been increasing. This study aimed to identify drugs associated with vitiligo using the FDA Adverse Event Reporting System (FAERS).
Methods: A retrospective disproportionality analysis was performed on FAERS reports from the first quarter of 2004 to the fourth quarter of 2024.